Rapitus (levodropropizin) syrup 120 ml. vial

Description

Rapitus (levodropropizin) syrup 120 ml. vial

Composition

active substance: levodropropizine;

5 ml of syrup contain levodroprozin 30 mg;

excipients: sodium saccharin, sodium methyl parahydroxybenzoate (E 219), sodium propyl parahydroxybenzoate (E 217), sodium carboxymethylcellulose; sorbitol solution, not crystallizing (E 420); citric acid, monohydrate; Ponceau 4R (E 124), orange flavor, RSV fruit mixture, propylene glycol, purified water.

Dosage form

Syrup.

Basic physical and chemical properties: red liquid with a fragrant smell.

Pharmacological group

Antitussives, with the exception of combined preparations containing expectorants.
Code ATX R05D B27.

Pharmacological properties 

Levodropropizin is an antitussive mainly of peripheral action, which helps to reduce the frequency and intensity of cough, has a bronchodilator effect. Unlike other antitussives, there is no tolerance or dependence on levodropropizine. Its effect on the central nervous system is much smaller than that of dropropizine. The effectiveness of levodropropizine is due to the suppression of the sensitivity of the receptors of the bronchial tree. The effectiveness of the drug has been proven in clinical trials and is over 90%. Levodropropizine acts at the level of nerve receptors by inhibiting the conduction of nerve impulses through C-fibers. Inhibits the release of neuropeptides, such as substance P and others, as well as histamine, thus achieving a significant bronchodilator effect.

Indication

Symptomatic treatment of dry nonproductive cough in pharyngitis, laryngitis, tracheitis, tracheobronchitis, influenza, bronchial asthma, emphysema, chronic obstructive bronchitis, allergic and infectious-inflammatory diseases of the respiratory tract, as well as lung tumors.

Contraindication

Hypersensitivity to levodropropizin or to other components of the drug; the presence or excessive secretion of sputum, decreased mucociliary function (Cartagener’s syndrome, ciliary dyskinesia), severe liver and kidney dysfunction.

Use during pregnancy or breastfeeding

There are no data on the safety of levodropropizine during pregnancy or breastfeeding, so the drug should not be prescribed during this period.

Method of application and dosage

The drug Rapitus is intended for oral administration.
The drug should be used 1 hour before or 2 hours after a meal.

Adults and children over 12 years of age should be prescribed 10 ml (equivalent to 60 mg of levodropropizine) 3 times a day at intervals of at least 6 hours.

Children aged 2 to 12 years should be administered at a dose of 1 mg / kg body weight 3 times a day, the total daily dose is 3 mg / kg body weight. For convenience, you can use the following approximate doses:

• children weighing 10-20 kg to use 3 ml up to 3 times a day;
• children weighing 20-30 kg apply 5 ml up to 3 times a day.

The duration of treatment is determined by the doctor and should not exceed 7 days. If symptoms persist within 4-5 days, treatment should be discontinued and consult a physician.

Children

The drug is contraindicated in children under 2 years.

Overdose:

• Symptoms: tachycardia, drowsiness, loss of consciousness, nausea, vomiting or increased manifestations of other side effects.
• Treatment: there is no specific antidote. It is necessary to wash out a stomach, to appoint sorbents and parenteral administration of plasma substitute solutions.
• Side effects
  From the digestive tract: nausea, vomiting, dyspepsia, heartburn, stomach discomfort, abdominal pain, diarrhea.
• From the nervous system: fatigue, asthenia, drowsiness, dizziness, headache, loss of consciousness, fainting, paresthesia.
• From the cardiovascular system: rapid heartbeat, tachycardia, cardiopathy.
• From the skin and subcutaneous tissue: skin rash, itching.

In case of individual intolerance to any component of the drug, including the dye ponso 4R, allergic reactions are possible.